-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Ranking of financing events in the healthcare industry in November
Ranking of financing events in the healthcare industry in NovemberActive investment institution: Yuansheng Venture Capital (5 cases)
Source: Firestone Creation Industry Data Center
【Financing Overview】A total of 94 investment and financing events occurred in the medical and health field nationwide this month, with a cumulative amount of more than 8.
214 billion yuan, compared with the financing situation last month, the number of invested projects decreased by 3.
09%, while the financing amount increased by 80.
41%.
09%, while the amount of financing increased by 80.
41%.
Figure 1: Financing in November 2022 Source: Flint Creation Industry Data Center
【Distribution of financing rounds】From the perspective of financing rounds, most of the financing events this month were concentrated in angel rounds and A rounds, with 23 and 18 projects invested respectively
.
In terms of financing amount, the highest financing amount for equity transfer was 3.
061 billion yuan, accounting for 37.
27% of the total financing amount; Secondly, Series B also received a higher financing amount of 1.
562 billion yuan, accounting for 19.
02%
of the total financing amount.
.
Figure 2: Number and amount of funding rounds this month Source: Firestone Creation Industry Data Center
【Geographical distribution of financing】This month's financing projects were mainly distributed in Guangdong Province (26 cases) and Jiangsu Province (21 cases).
In terms of financing amount, Yunnan Province is the most prominent, with a financing amount of 2.
902 billion yuan, accounting for 35.
33% of the total financing amount; Secondly, Guangdong Province is also more prominent, with a financing amount of 1.
618 billion yuan, accounting for 19.
70%
of the total financing amount.
Figure 3: Number and amount of financing by region this month Source: Firestone Creation Industry Data Center
【Distribution of financing amount】A total of 94 projects were invested this month, with a cumulative amount of more than 8.
214 billion yuan, and 27 cases with a single financing amount of more than 100 million yuan, with a total financing amount of 7.
419 billion yuan, accounting for 90.
32%
of the total financing scale this month.
214 billion yuan, and there were 27 cases with a single financing amount exceeding 100 million yuan,
Figure 4: Distribution of financing amounts this month Source: Firestone Creation Industrial Data Center
【The most popular area for investors】This month, pharmaceutical business attracted the most money, with a financing amount of 3.
002 billion yuan, accounting for 36.
55%
of the total financing amount.
In terms of the number of projects, the pharmaceutical field is also relatively active
.
Figure 5: Distribution of the number and amount of financing by sector this month Source: Firestone Creation Industry Data Center
The most noteworthy financing projects
The most noteworthy financing projectsCR Sanjiu plans to invest 2.
9 billion yuan in KunYao Group
9 billion yuan in KunYao Group
On November 29, China Resources Sanjiu (000999.
SZ) announced that the company intends to purchase 208,976,160 shares of KunYao Group held by it (accounting for 27.
56% of the total issued shares of KunYao Group) from Holley Pharmaceutical by way of cash payment, and purchase 3,335,456 shares of KunYao Group (0.
44% of the total issued shares of KunYao Group)
from Holley Group.
After the completion of this transaction, the company will hold a total of 212,311,616 shares of KunYao Group (accounting for 28% of the total issued shares of KunYao Group) and become the controlling shareholder of KunYao Group, and the price of the above-mentioned subject shares is proposed to be 290,200,000 yuan, corresponding to the transfer price per share of KunYao Group of 13.
67 yuan per share
.
Zenash Biologics received $118 million in Series B financing
Zenash Biologics received $118 million in Series B financingZenas BioPharma announced that it received $118 million in Series B funding
.
This round of funding was raised by Enavate
Sciences led the investment, followed by other investors such as Vivo Capital
.
Zenash Biologics was founded in 2021 to develop immunotherapy drugs
.
The company's founder and executive chairman is Lonnie
Mr.
Moulder, the company's Chief Executive Officer (CEO) is Dr.
Mou Hua.
According to the press release, the funding will be used to support the clinical trial of the company's main drug candidate, obexelimab, and to advance the company's other global autoimmune disease programs into clinical development
in 2023.
Techno Bio completed a pre-IPO round of financing of 750 million yuan
Techno Bio completed a pre-IPO round of financing of 750 million yuanRecently, TechnoMaab Biologics announced the completion of a pre-IPO round of financing of about 750 million yuan
.
This round of financing was led by Gree Gold Investment and Xicheng Jinrui, followed by Yifeng Capital, Shenhong Gejin, Jiaxing Weilong, Haichuang Anda, Xintaige, Qinwan Capital, etc.
, and the old shareholders Kangzhe Pharmaceutical, Wuxi Guolian and Jinhang Group continued to increase their weight
.
Based on the Natural Fully Human Monoclonal Antibody R&D Integrated Technology Platform (HitmAb®), Technolab Biologics develops a new natural fully human monoclonal antibody drug
.
At present, the company's TNM001 injection (anti-RSV long-acting monoclonal antibody) and TNM002 injection (anti-tetanus toxin monoclonal antibody) products have entered the clinical stage
.
Lupeng Pharma completed a $35 million financing
Lupeng Pharma completed a $35 million financingRecently, Lupeng Pharmaceutical Ltd.
Lupeng Pharmaceutical Co.
, Ltd.
("Lupeng Pharmaceutical") successfully completed the second phase of the pre-B round
financing with a total of US$35 million.
The second tranche of the pre-B round was led by Cathay Capital and Temasek, and Lilly Asia Fund
(LAV), Toyokawa Capital, Qingchi Capital and other strategic investors followed
.
Lupeng Pharmaceutical was established
in Guangzhou in June 2018.
The company focuses on the research and development of innovative drugs that seriously affect human life and health such as malignant tumors, autoimmune diseases and hepatitis B, and has a world-class drug design team, focusing on targets with difficult drug design, few competitors, emerging clinical resistance mutations, or major defects in existing drugs;
Focus on developing targets that have strong synergies with existing core projects (e.
g.
, Bcl-2
).
The company's R&D pipeline has more than 10 projects, including core projects LP-168, LP-108 and LP-118
With world-class competitiveness, targeting the global market
.
Clinical trials
have been conducted in China, the United States and Europe.
Since its establishment, the company has continuously received more than 110 million US dollars of investment from well-known venture capital funds in the field of biomedicine, which is used for early development and clinical research
of projects.
In 2021, it won the titles of National High-tech Enterprise, Guangzhou Future Unicorn Innovation Enterprise and Guangzhou High-precision Enterprise
.
In order to meet the rapid development of the company's business, the construction of the Group's headquarters building, R&D and production base in the Sino-Singapore Knowledge City in the Greater Bay Area of Guangzhou will be fully launched in the near future, covering an area of 20,000 square meters and a construction area of more than 60,000 square meters, which is expected to be completed and put into use
in 2025-2026.
Adhering to the concept of "diligence, pragmatism, innovation and prosperity", Lupeng Pharmaceutical is committed to building a multinational pharmaceutical enterprise
headquartered in the Greater Bay Area that integrates R&D, production and sales, and has high innovation and high sense of social responsibility.
Bangyao Biotech completed a series B financing of more than 200 million yuan
Bangyao Biotech completed a series B financing of more than 200 million yuanShanghai Bangyao Biotechnology Co.
, Ltd.
(hereinafter referred to as "Bangyao Biotechnology"), which focuses on gene and cell therapy, has completed a series B financing
of more than RMB 200 million.
This round of financing was led by Shanghai Free Trade Zone Fund, with Oriental Fuhai, Tasly Capital, Betta Fund, Gopher Asset and others
.
After this round of financing, Bangyao Biotech will continue to promote the transformation and landing of cell and gene drugs, and increase efforts to further accelerate the global R&D layout, help the development of global life sciences, and bring hope
to patients with genetic diseases, malignant tumors and autoimmune system diseases around the world.
Founded in 2013, Bang Yao Biotech is an innovative pharmaceutical company
focusing on the field of gene and cell therapy, with the mission of "leading innovation with gene editing, developing breakthrough therapies for the benefit of all mankind" 。 The core management team of Bangyao Biotech includes a number of world-class top experts in the field of CGT, Dr.
Liu Mingyao, founder and chairman of Bangyao Biotechnology, is the first batch of national distinguished experts and national chair professors, and has won the first prize of National Science and Technology Progress Award and the first prize of Shanghai Science and Technology Progress Award; Dr.
Zheng Biao, CEO of Bang Yao Biologics, is an authoritative expert in the field of immunology, and has served as a tenured professor in the Department of Pathology and Immunology at Baylor College of Medicine, and was the head of immune disease research and development at GSK, and the global vice president of Johnson & Johnson
.
The gene editing platform of Bangyao Biotech is led
by Professor Li Dali, co-founder and vice president of the company, and a well-known gene editing leader at home and abroad.
At present, relying on the profound academic accumulation of the core team, Bangyao Biotech is committed to deeply exploring gene editing and transformation scenarios, establishing a solid patent foundation, and transforming the results into a potential commercialization pipeline, and confirming good druggability
in a number of IIT trials 。 Among them, gene editing for the treatment of β-thalassemia is the world's first project to successfully treat β0/β0 severe thalassemia through gene editing technology, showing the world's best clinical effect, and has obtained IND approval in August 2022 and officially entered clinical phase I/II studies; The non-viral PD1 fixed-point integration CAR-T project adopts a revolutionary and innovative technology path, the preparation cost is significantly lower than that of viral CAR-T products, the preparation cycle is shorter, and the clinical effect is better, and it is expected to be approved for IND within this year, and the above pipelines and the company's research and development results in UCART and other projects have obtained Nature, Nature
Medicine、Nature
Biotechnology and many other world-class journals and domestic and foreign R&D and clinical experts in related fields are recognized and continuously optimistic, and are currently entering the stage
of milestone harvest.
After years of continuous cultivation in the field of CGT, Bangyao Biotech has become a global leader in the field of gene and cell therapy
.
